Fig. 2From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in ItalyDistribution of patients by baseline BCVA in the study eye [Source: [10, 13, 14]]. BCVA Best Corrected Visual AcuityBack to article page